Research programme: bispecific antibodies - Micromet/Sanofi

Drug Profile

Research programme: bispecific antibodies - Micromet/Sanofi

Alternative Names: Cancer therapy - Micromet/Sanofi

Latest Information Update: 30 Jul 2012

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Micromet Inc; Sanofi
  • Class Bispecific antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 26 Jul 2012 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 02 Mar 2012 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top